This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters To the Editor

Six-Month Review of Weight and Metabolic Parameters in Patients Receiving Clozapine, Risperidone, Olanzapine, or Quetiapine

Deanna L. Kelly, Julie Kreyenbuhl, Raymond C. Love, Quynh Van-Duong, and Robert R. Conley

Published: September 1, 2003

Article Abstract

Letter to the Editor

Six-Month Review of Weight and Metabolic Parameters in Patients Receiving Clozapine, Risperidone, Olanzapine, or Quetiapine


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 64

Quick Links: Metabolic Disorder , Side Effects-Medication

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Young-Adult Social Outcomes of Attention-Deficit/Hyperactivity Disorder

ADHD that persisted into young-adulthood was associated with poorer outcomes in terms of education, employment, and emotional...

Read More...